While our results do not rule out inhibitory roles for tumor-expressed IL-6 on CD103+ cDC1 function, we anticipate CD103+ cDC1s are refractory to tumor-derived LIF or G-CSF due to the relatively low abundance of receptor mRNAs in this subset relative to other immune populations [31]. The gene discussed is CSF3; the disease is neoplasm.